{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-004528","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.651839+00:00","generated_at":"2026-06-04T04:55:03.575393+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Xilio reports FY2023 net loss of $76.4M, Gilead licenses XTX301 for up to $604M","bullets":["Cash and cash equivalents were $44.7M at Dec 31, 2023, down from $120.4M a year earlier.","Net loss was $17.7M for Q4 2023 and $76.4M for FY2023, vs $22.5M and $88.2M in 2022.","Gilead pays $43.5M upfront ($30M cash + $13.5M equity) for exclusive license to XTX301; Xilio eligible for up to $604M in milestones and tiered royalties.","Plans to initiate Phase 2 trial of XTX101 + atezolizumab in MSS CRC in Q3 2024, with initial data in Q4 2024.","Cash runway extended into Q2 2025 after Gilead upfront, $11.3M private placement, and workforce reduction of ~21%."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-004528","json":"https://secwatch.observer/filing/0001558370-24-004528.json","markdown":"https://secwatch.observer/filing/0001558370-24-004528.md","text":"https://secwatch.observer/filing/0001558370-24-004528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024004528/0001558370-24-004528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024004528/xlo-20240401x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:55:03.575393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e93978c1196b6dc0227dc38bea42ab66f7528436","claim":"Xilio Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024004528/0001558370-24-004528-index.htm","confidence":0.93,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}